Research has suggested that the decreased platelet counts observed in ITP patients with anti-GPIbα antibodies may be attributed to the activation of the PI3K pathway induced by the anti-GPIbα antibody, leading to AKT activation, a downstream effector of PI3K (66). Here, AKT1 is linked to autoimmune thrombocytopenic purpura.